The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors

Antibodies against immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple aggressive malignancies, including melanoma and non-small cell lung cancer. ICIs for the treatment of primary and metastatic brain tumors have been used with varying degrees of success. Here, we disc...

Descripción completa

Detalles Bibliográficos
Autores principales: Alimonti, Paolo, Gonzalez Castro, L. Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123751/
https://www.ncbi.nlm.nih.gov/pubmed/37092448
http://dx.doi.org/10.3390/antib12020027
_version_ 1785029726877777920
author Alimonti, Paolo
Gonzalez Castro, L. Nicolas
author_facet Alimonti, Paolo
Gonzalez Castro, L. Nicolas
author_sort Alimonti, Paolo
collection PubMed
description Antibodies against immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple aggressive malignancies, including melanoma and non-small cell lung cancer. ICIs for the treatment of primary and metastatic brain tumors have been used with varying degrees of success. Here, we discuss the available evidence for the use of ICIs in the treatment of primary and metastatic brain tumors, highlighting challenges and opportunities for furthering this type of cancer immunotherapy in neuro-oncology.
format Online
Article
Text
id pubmed-10123751
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101237512023-04-25 The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors Alimonti, Paolo Gonzalez Castro, L. Nicolas Antibodies (Basel) Review Antibodies against immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple aggressive malignancies, including melanoma and non-small cell lung cancer. ICIs for the treatment of primary and metastatic brain tumors have been used with varying degrees of success. Here, we discuss the available evidence for the use of ICIs in the treatment of primary and metastatic brain tumors, highlighting challenges and opportunities for furthering this type of cancer immunotherapy in neuro-oncology. MDPI 2023-04-04 /pmc/articles/PMC10123751/ /pubmed/37092448 http://dx.doi.org/10.3390/antib12020027 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Alimonti, Paolo
Gonzalez Castro, L. Nicolas
The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors
title The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors
title_full The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors
title_fullStr The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors
title_full_unstemmed The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors
title_short The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors
title_sort current landscape of immune checkpoint inhibitor immunotherapy for primary and metastatic brain tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123751/
https://www.ncbi.nlm.nih.gov/pubmed/37092448
http://dx.doi.org/10.3390/antib12020027
work_keys_str_mv AT alimontipaolo thecurrentlandscapeofimmunecheckpointinhibitorimmunotherapyforprimaryandmetastaticbraintumors
AT gonzalezcastrolnicolas thecurrentlandscapeofimmunecheckpointinhibitorimmunotherapyforprimaryandmetastaticbraintumors
AT alimontipaolo currentlandscapeofimmunecheckpointinhibitorimmunotherapyforprimaryandmetastaticbraintumors
AT gonzalezcastrolnicolas currentlandscapeofimmunecheckpointinhibitorimmunotherapyforprimaryandmetastaticbraintumors

Ejemplares similares